Table 1.
General comparison between each direct oral anticoagulation drug and Vitamin-K antagonist
| Warfarin | Apixaban | Dabigatran | Edoxaban | Rivaroxaban | Total | |
|---|---|---|---|---|---|---|
| n (%) | 553 (68.4) | 130 (16.1) | 58 (7.2) | 4 (0.5) | 63 (7.8) | 808 (100) |
| Mean age (+/− SD) | 54.7 (13.7) | 61.2 (12.4) | 56.9 (12.5) | 48.3 (18.9) | 60.2 (15.7) | 56.3 (13.8) |
| Females, n (%) | 331 (59.9) | 78 (60.0) | 20 (34.5) | 4 (100) | 31 (49.2) | 464 (57.4) |
| Saudi nationality, n (%) | 544 (98.4) | 130 (100) | 57 (98.3) | 4 (100) | 62 (98.4) | 797 (98.6) |
| Bachelor degree or higher, n (%) | 144 (26.0) | 27 (20.8) | 25 (43.1) | 1 (25.0) | 13 (20.6) | 210 (26.0) |
| Indication for anticoagulation intake, n (%) | ||||||
| • Heart valve disease | 252 (45.6) | 13 (10.0) | 20 (34.5) | 0 (0.0) | 7 (11.1) | 292 (36.1) |
| • Vein thrombosis | 104 (18.8) | 18 (13.8) | 9 (15.5) | 3 (75.0) | 17 (27.0) | 151 (18.7) |
| • Heart rhythm disease | 40 (7.2) | 56 (43.1) | 15 (25.9) | 0 (0.0) | 13 (20.6) | 124 (15.3) |
| • Other cardiological diseasesa | 47 (8.5) | 21 (16.2) | 7 (12.1) | 1 (25.0) | 10 (15.9) | 86 (10.6) |
| • Stroke | 52 (9.4) | 13 (10.0) | 3 (5.2) | 0 (0.0) | 12 (19.0) | 80 (9.9) |
| • Pulmonary diseasesb | 22 (4.0) | 4 (3.1) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 27 (3.3) |
| • Multiple indications | 16 (2.9) | 1 (0.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 17 (2.1) |
| • Other indicationsc | 18 (3.3) | 3 (2.3) | 2 (3.4) | 0 (0.0) | 3 (4.8) | 26 (3.2) |
| • Not known | 2 (0.4) | 1 (0.8) | 1 (1.7) | 0 (0.0) | 1 (1.6) | 5 (0.6) |
| Patients on BID regimen, n (%) | 37 (6.7) | 80 (61.5) | 18 (31.0) | 0 (0.0) | 19 (30.2) | 154 (19.1) |
| Share of typical anticoagulation dosages, mg (n; %) |
3 (96; 17.4) 6 (29; 5.2) |
2.5 (50; 38.5) 5 (71; 54.6) |
110 (4; 6.9) 150 (24; 41.4) |
30 (3; 75) 60 (1; 25) |
10 (27; 42.9) 20 (14; 22.2) |
|
aOther cardiological diseases including: coronary heart disease, previous myocardial infarctions and cardiomyopathies
bPulmonary diseases including: pulmonary embolism and pulmonary artery hypertension
cOther indications including: antiphospholipid syndrome and other coagulation disorders